Literature DB >> 18726676

Drug therapy and personalized health care: pharmacogenomics in perspective.

Wolfgang Sadee1.   

Abstract

Mesh：

Substances：

Year:  2008        PMID： 18726676     DOI： 10.1007/s11095-008-9702-4

Source DB:  PubMed          Journal:  Pharm Res        ISSN： 0724-8741            Impact factor:   4.200


× No keyword cloud information.
  22 in total

1.  Allelic expression imbalance of human mu opioid receptor (OPRM1) caused by variant A118G.

Authors:  Ying Zhang; Danxin Wang; Andrew D Johnson; Audrey C Papp; Wolfgang Sadée
Journal:  J Biol Chem       Date:  2005-07-26       Impact factor: 5.157

2.  Impaired expression of CYP2D6 in intermediate metabolizers carrying the *41 allele caused by the intronic SNP 2988G>A: evidence for modulation of splicing events.

Authors:  Claudia Toscano; Kathrin Klein; Julia Blievernicht; Elke Schaeffeler; Tanja Saussele; Sebastian Raimundo; Michel Eichelbaum; Matthias Schwab; Ulrich M Zanger
Journal:  Pharmacogenet Genomics       Date:  2006-10       Impact factor: 2.089

3.  Polymorphisms affecting gene transcription and mRNA processing in pharmacogenetic candidate genes: detection through allelic expression imbalance in human target tissues.

Authors:  Andrew D Johnson; Ying Zhang; Audrey C Papp; Julia K Pinsonneault; Jeong-Eun Lim; David Saffen; Zunyan Dai; Danxin Wang; Wolfgang Sadée
Journal:  Pharmacogenet Genomics       Date:  2008-09       Impact factor: 2.089

4.  Genetic testing for everyone.

Authors:  Helen Pearson
Journal:  Nature       Date:  2008-05-29       Impact factor: 49.962

5.  Microbiology: the inside story.

Authors:  Asher Mullard
Journal:  Nature       Date:  2008-05-29       Impact factor: 49.962

Review 6.  Genetic contribution to variable human CYP3A-mediated metabolism.

Authors:  Jatinder K Lamba; Yvonne S Lin; Erin G Schuetz; Kenneth E Thummel
Journal:  Adv Drug Deliv Rev       Date:  2002-11-18       Impact factor: 15.470

7.  Tryptophan hydroxylase 2 (TPH2) haplotypes predict levels of TPH2 mRNA expression in human pons.

Authors:  J-E Lim; J Pinsonneault; W Sadee; D Saffen
Journal:  Mol Psychiatry       Date:  2006-12-12       Impact factor: 15.992

8.  Regulatory polymorphism in vitamin K epoxide reductase complex subunit 1 (VKORC1) affects gene expression and warfarin dose requirement.

Authors:  Danxin Wang; Huizi Chen; Kathryn M Momary; Larisa H Cavallari; Julie A Johnson; Wolfgang Sadée
Journal:  Blood       Date:  2008-06-03       Impact factor: 22.113

9.  MicroRNAs modulate the chemosensitivity of tumor cells.

Authors:  Paul E Blower; Ji-Hyun Chung; Joseph S Verducci; Shili Lin; Jong-Kook Park; Zunyan Dai; Chang-Gong Liu; Thomas D Schmittgen; William C Reinhold; Carlo M Croce; John N Weinstein; Wolfgang Sadee
Journal:  Mol Cancer Ther       Date:  2008-01-09       Impact factor: 6.261

10.  Pharmacogenetic testing of CYP2C9 and VKORC1 alleles for warfarin.

Authors:  David A Flockhart; Dennis O'Kane; Marc S Williams; Michael S Watson; David A Flockhart; Brian Gage; Roy Gandolfi; Richard King; Elaine Lyon; Robert Nussbaum; Dennis O'Kane; Kevin Schulman; David Veenstra; Marc S Williams; Michael S Watson
Journal:  Genet Med       Date:  2008-02       Impact factor: 8.822
View more
  3 in total

1.  Delivered dose: a drug-centric phenotype for chemotherapy dose individualization.

Authors:  Y Bruce Yu
Journal:  Pharm Res       Date:  2009-06-03       Impact factor: 4.200

Review 2.  Maternal-fetal and neonatal pharmacogenomics: a review of current literature.

Authors:  Y J Blumenfeld; M F Reynolds-May; R B Altman; Y Y El-Sayed
Journal:  J Perinatol       Date:  2009-11-19       Impact factor: 2.521

Review 3.  Pharmacogenomics of human ABC transporter ABCC11 (MRP8): potential risk of breast cancer and chemotherapy failure.

Authors:  Yu Toyoda; Toshihisa Ishikawa
Journal:  Anticancer Agents Med Chem       Date:  2010-10-01       Impact factor: 2.505
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.